The goals of the present study using a novel assay for pTau were to examine and compare levels of plasma phospho-tau181 (pTau181) and plasma total tau by clinical diagnosis across the AD spectrum
Resources by Therapeutic Area
Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography
Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis
The objective of the study was to investigate the association between sNfL and clinical and MRI measurements in a therapy-naive cohort of CIS and RRMS patients in the very early stage of disease.
Clostridium difficile infection (CDI) is a serious and sometimes life-threatening illness caused by toxin release from Clostridium difficile (CD), a gram-positive anaerobic bacterium. Infection with CD can cause clinical manifestations in a spectrum from asymptomatic carrier states to pseudomembrano…
Progressive cerebral accumulation of tau aggregates is a defining feature of Alzheimer’s disease (AD). A popular theory that seeks to explain the apparent spread of neurofibrillary tangle pathology proposes that aggregated tau is passed from neuron to neuron. Such a templated seeding process require…
Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression
A blood-based biomarker of neuronal damage in sporadic Creutzfeldt-Jakob disease (sCJD) will be extremely valuable for both clinical practice and research aiming to develop effective therapies.